FDMT Q3 2024 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3,000-100.0% YoY

Gross Profit

$3,000100.0% margin

Operating Income

-$51M-1704400.0% margin

Net Income

-$44M-1461433.3% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

-40.0%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$31M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$604M

Total Liabilities

$51M

Stockholders' Equity

$553M

Cash & Equivalents

$188M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3,000	$20M	-100.0%
Gross Profit	$3,000	-$5M	+100.1%
Operating Income	-$51M	-$14M	-265.9%
Net Income	-$44M	-$10M	-327.5%

Revenue Segments

Collaboration And License Revenue

$3,000100%

Geographic Segments

UNITED STATES

$3,000100%